Profile of Hepatitis C & Injection Drug Use in Canada

Prepared for:
Hepatitis C Prevention, Support & Research Program
Population & Public Health Branch
Health Canada
September 2000

This document was prepared by Jamie Wiebe on behalf of the Canadian Centre on Substance Abuse (CCSA), in collaboration with Bette Reimer, information specialist contracted by the CCSA to help conduct this review.

The views expressed herein, are solely those of the authors and do not necessarily reflect the official policies of Health Canada.

For further information about this publication or for copies, please contact:

Hepatitis C Division
Centre for Infectious Disease Prevention and Control
Population and Public Health Branch
Health Canada
2nd Floor, 400 Cooper Street
Ottawa, Ontario
K1A 0K9

Tel.: (613) 941-7532
Fax: (613) 941-7563
Web site: www.hc-sc.gc.ca

Ce document est disponible en français.

---

Table of Contents

• EXECUTIVE SUMMARY
• INTRODUCTION
• METHODOLOGY
• EPIDEMIOLOGY OF HCV
  • PREVALENCE & INCIDENCE
  • MODES OF TRANSMISSION
  
  
• IDU IN CANADA
  • PREVALENCE OF IDU
  •  TYPES OF DRUGS
  •  NEEDLE-SHARING
  •  DEMOGRAPHIC CHARACTERISTICS
  
  
• HCV IN IDU POPULATIONS
  • CANADA
  • INTERNATIONAL
  
  
• HCV AND AT-RISK POPULATIONS
  • STREET-INVOLVED YOUTH
  •  WOMEN
  • ABORIGINAL PEOPLE IN CANADA
  • PRISON POPULATIONS
  
  
• CONSIDERATIONS FOR INTERVENTION
• SUMMARY
• REFERENCES
• APPENDIX